Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence

• Published in: Current medical research and opinion 2011-11, Vol.27 (11), p.2185-2191
• Main Authors: Rothrock, John F., Cady, Roger K., Aurora, Sheena K., Brandes, Jan Lewis, Myers, Judith A., Fox, Anthony W., Farr, Stephen J.
• Format: Article
• Language: English
• Subjects: 1B/1D; 5HT; Adolescent; Adult; Aged; agonist; Drug Administration Routes; Drug Delivery Systems - methods; Female; Headache; Humans; Injection; Male; Middle Aged; Migraine; Migraine Disorders - drug therapy; Patient Satisfaction; Satisfaction; Serotonin 5-HT1 Receptor Agonists - administration & dosage; Serotonin 5-HT1 Receptor Agonists - therapeutic use; Sumatriptan; Sumatriptan - administration & dosage; Sumatriptan - therapeutic use; Treatment Outcome; Triptan; Tryptamines - therapeutic use; Young Adult
• ISSN: 0300-7995; 1473-4877
• DOI: 10.1185/03007995.2011.619177

Abstract Objective: To evaluate efficacy of, satisfaction with, and confidence in SDP (SUMAVEL DosePro*) among triptan users requiring a change in therapy. SDP is a needle-free, subcutaneous sumatriptan product that confers relief as early as 10 minutes postdose. *SUMAVEL and DosePro are registered trademarks of Zogenix Inc., Emeryville and San Diego, CA, USA. Research design and methods: In an open-label study, SDP was administered for 4 migraine attacks over 60 days by migraineurs currently treated with triptans (any form/dosage). In the 90 patients with baseline Migraine-ACT scores 2 (indicating the need for a change in therapy), efficacy data were collected from patient diaries, and satisfaction was measured with the revised Patient Perception of Migraine Questionnaire (PPMQ-R). Clinical trial registration number: NCT01016834 on clinicaltrials.gov. Results: Across all attacks, the rates of pain relief were 30.7%, 66.4%, 80.1%, 81.6%, and 77.6% at 0.25, 0.5, 1, 2, and 24 hours postdose, respectively. Corresponding results for pain-free response were 0.7%, 14.8%, 35.0%, 48.0, and 65.7%. Sustained 24-hour pain relief was observed in 61.0% of attacks. PPMQ-R scores (transformed to 0-100 scales, mean ± SD) improved from baseline to end of treatment for Efficacy (52.5 ± 17.8 versus 74.8 ± 23.4, p